138 related articles for article (PubMed ID: 22504414)
21. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract.
Ohtsuka Y; Kawakami S; Fujii Y; Koga F; Saito K; Ando N; Takizawa T; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1322-6. PubMed ID: 16686732
[TBL] [Abstract][Full Text] [Related]
22. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
[TBL] [Abstract][Full Text] [Related]
23. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial.
Bolenz C; Herrmann E; Bastian PJ; Michel MS; Wülfing C; Tiemann A; Buchner A; Stief CG; Fritsche HM; Burger M; Wieland WF; Höfner T; Haferkamp A; Hohenfellner M; Müller SC; Ströbel P; Trojan L
BJU Int; 2010 Aug; 106(4):493-9. PubMed ID: 20067452
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
[TBL] [Abstract][Full Text] [Related]
25. Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy.
Denzinger S; Stoehr R; Schwarz S; Eichenseher N; Brockhoff G; Obermann EC; Knuechel R; Blaszyk H; Hartmann A; Wild PJ
Int J Oncol; 2007 Oct; 31(4):793-802. PubMed ID: 17786310
[TBL] [Abstract][Full Text] [Related]
26. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
[TBL] [Abstract][Full Text] [Related]
27. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis.
Nischalke HD; Berger C; Aldenhoff K; Thyssen L; Gentemann M; Grünhage F; Lammert F; Nattermann J; Sauerbruch T; Spengler U; Appenrodt B
J Hepatol; 2011 Nov; 55(5):1010-6. PubMed ID: 21356257
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years' research.
Skagias L; Politi E; Karameris A; Sambaziotis D; Archondakis A; Vasou O; Ntinis A; Michalopoulou F; Moreas I; Koutselini H; Patsouris E
J BUON; 2009; 14(3):457-62. PubMed ID: 19810139
[TBL] [Abstract][Full Text] [Related]
29. Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma.
Rioja J; Bandrés E; Rosell Costa D; Rincón A; López I; Zudaire Bergera JJ; García Foncillas J; Gil MJ; Panizo A; Plaza L; Rioja LA; Berián Polo JM
BJU Int; 2011 Jun; 107(11):1833-8. PubMed ID: 20840328
[TBL] [Abstract][Full Text] [Related]
30. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
[TBL] [Abstract][Full Text] [Related]
31. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
[TBL] [Abstract][Full Text] [Related]
32. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
33. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
34. Association between Genetic Polymorphisms of Inflammatory Response Genes and Acute Pancreatitis.
Rodriguez-Nicolas A; Jiménez P; Carmona FD; Martín J; Matas Cobos AM; Ruiz-Cabello F; Redondo-Cerezo E
Immunol Invest; 2019 Aug; 48(6):585-596. PubMed ID: 31044631
[TBL] [Abstract][Full Text] [Related]
35. The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation.
Holler E; Rogler G; Brenmoehl J; Hahn J; Greinix H; Dickinson AM; Socie G; Wolff D; Finke J; Fischer G; Jackson G; Rocha V; Hilgendorf I; Eissner G; Marienhagen J; Andreesen R
Int J Immunogenet; 2008 Aug; 35(4-5):381-4. PubMed ID: 18976442
[TBL] [Abstract][Full Text] [Related]
36. Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study.
Galluzzo S; Patti G; Dicuonzo G; Di Sciascio G; Tonini G; Ferraro E; Spoto C; Campanale R; Zoccoli A; Angeletti S
Hum Immunol; 2011 Aug; 72(8):636-40. PubMed ID: 21565239
[TBL] [Abstract][Full Text] [Related]
37. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
38. High CD10 expression predicts favorable outcome in surgically treated lymph node-positive bladder cancer patients.
Seiler R; von Gunten M; Thalmann GN; Fleischmann A
Hum Pathol; 2012 Feb; 43(2):269-75. PubMed ID: 21835428
[TBL] [Abstract][Full Text] [Related]
39. Behavior of urothelial carcinoma with respect to anatomical location.
Catto JW; Yates DR; Rehman I; Azzouzi AR; Patterson J; Sibony M; Cussenot O; Hamdy FC
J Urol; 2007 May; 177(5):1715-20. PubMed ID: 17437794
[TBL] [Abstract][Full Text] [Related]
40. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers.
Sgambato A; Migaldi M; Faraglia B; Garagnani L; Romano G; De Gaetani C; Ferrari P; Capelli G; Trentini GP; Cittadini A
Cancer Res; 1999 Jul; 59(13):3245-50. PubMed ID: 10397272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
